Clopidogrel

Modify Date: 2024-01-02 21:52:58

Clopidogrel structure	Common Name	Clopidogrel
	CAS Number	113665-84-2	Molecular Weight	321.822
	Density	1.3±0.1 g/cm3	Boiling Point	423.7±45.0 °C at 760 mmHg
	Molecular Formula	C₁₆H₁₆ClNO₂S	Melting Point	N/A
	MSDS	N/A	Flash Point	210.0±28.7 °C

Use of Clopidogrel

Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Name	clopidogrel
Synonym	More Synonyms

Description	Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> P2Y Receptor Research Areas >> Cardiovascular Disease
Target	P2Y12 receptor[1].
In Vivo	Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis[1]. The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS[2].
Animal Admin	Mice[1] 13-week-old C57BL/6J male mice are used throughout the study. After 1 week of acclimation, 15 mice are injected I.P. with streptozotocin (STZ) at a dosage of 55 mg/kg body weight daily for five consecutive days. Additional 15 mice as controls (Ctrl) are injected with a vehicle solution (0.1 mol/L citrate acid buffer, pH 4.3-4.5). Seven days after the last STZ administration, hyperglycemic mice (3-hour fasting blood glucose ≥250 mg/dL) are considered T1D (DM). This time point is defined as a baseline. Three months after diabetes induction, five diabetic and five control mice are sacrificed and blood and kidneys harvested. The remaining animals are divided in four groups: Normal control with vehicle (Ctrl), Normal control with Clopidogrel (Ctrl+ Clo), T1D (DM) with vehicle, and DM with Clopidogrel treatment (DM+Clo) and are treated with 20 mg/kg b.w./day Clopidogrel or with vehicle administered in their drinking water for three additional months. At the end of experiment, mice are intraperitoneally anesthetized with Avertin (tribromoethanol, 350 mg/kg) and sacrificed to collect blood and kidneys for mRNA, protein, and histological analyses[1].
References	[1]. Zongyu Zheng, et al. Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis. Int J Biol Sci. 2019 Jan. [2]. An insight into the interaction between clopidogrel and proton pump inhibitors By Shah, Bhavik S.; Parmar, Sanjay A.; Mahajan, Shailaja; Mehta, Anita A. From Current Drug Metabolism (2012), 13(2),225-235.

Density	1.3±0.1 g/cm3
Boiling Point	423.7±45.0 °C at 760 mmHg
Molecular Formula	C₁₆H₁₆ClNO₂S
Molecular Weight	321.822
Flash Point	210.0±28.7 °C
Exact Mass	321.059021
PSA	57.78000
LogP	4.23
Vapour Pressure	0.0±1.0 mmHg at 25°C
Index of Refraction	1.617
Storage condition	2-8℃

Hazard Codes	Xn:Harmful
Risk Phrases	R22
Safety Phrases	S36/37-S22
WGK Germany	3

Precursor 9
CAS#:120202-66-6 Clopidogrel bis... CAS#:144457-28-3 CLOPIDOGRELCARB... CAS#:67-56-1 Methanol CAS#:90055-47-3 Methyl chloro(2...
CAS#:54903-50-3 4,5,6,7-Tetrahy... CAS#:141109-20-8 methyl (2S)-2-(... CAS#:50-00-0 Formaldehyde CAS#:144750-42-5 2-Methoxyethyl ...
CAS#:77-78-1 Dimethyl sulfate
DownStream 4
CAS#:144457-28-3 CLOPIDOGRELCARB... CAS#:144750-42-5 2-Methoxyethyl ... CAS#:120202-66-6 Clopidogrel bis... CAS#:90055-48-4 (±)-Clopidogrel